Click here for slides on this topic


ACCORD

ACCORD was a randomized, multicenter, double 2X2 factorial trial in 10,251 patients with type 2 diabetes mellitus designed to test the effects on major cardiovascular disease (CVD) events of intensive glycemia control, of fibrate treatment to increase HDL-cholesterol and lower triglycerides, and of intensive blood pressure control, each compared to an appropriate control. All 10,251 participants were in an overarching glycemia trial.
The following content matched the glossary term: ACCORD

AHA ADA prevention of CVD in T2D - Hypoglycemia & CVD

Top

Summary of evidence for hypoglycemia & cardiovascular disease (CVD) from the AHA ADA CVD prevention in type 2 diabetes guidelines.

NDEI.org Expert Commentary Silvio E. Inzucchi MD on the Association Between Severe Hypoglycemia

Top

EXPERT COMMENTARY Expert blog post from Silvio E. Inzucchi, MD: "This paper adds to a growing body of literature demonstrating the higher cardiovascular risk of patients with type 2 diabetes and a history of severe hypoglycemia"

Effect of hypoglycemia on brain structure in people with type 2 diabetes: epidemiological analysis of the ACCORD-MIND MRI trial

Top

Zhang Z, Lovato J, Battapady H, et al. Effect of hypoglycemia on brain structure in people with type 2 diabetes:  epidemiological analysis of the ACCORD MIND MRI trial. Diabetes Care. 2014;37(12):3279-3285.

Clinical Insights in Diabetes Newsletter July 2013

Top

Clinical Insights® in Diabetes newsletter July 2013

Carotid intima-media thickness (CIMT) change in ORIGIN-GRACE, effects of omega-3 fatty acids on CV events in the Risk and Prevention Study, canagliflozin therapy in CANTATA-D2 and CANTATA-M, weight gain and intensive therapy in ACCORD, glycemic control with single daily basal insulin plus corrective glulisine and basal bolus regimen, diurnal pattern to insulin action in type 1 diabetes.

Diabetic retinopathy, its progression and incident cardiovascular events in the ACCORD trial

Top

Gerstein HC, Ambrosius WT, Danis R, et al. Diabetic retinopathy, its progression and incident cardiovascular events in the ACCORD trial. Diabetes Care. 2013;36(5):1266-1271. The presence and severity of diabetic retinopathy are independent determinants of future cardiovascular events among individuals with diabetes. The present study analyzed data from a subset of participants from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study who were enrolled in the ACCORD Eye study.

Fonseca commentary on ADVANCE, SOS, VADT

Top

Expert commentary from NDEI Education Council Member Vivian A. Fonseca, MD, on data from post-hoc analyses of ADVANCE, SOS, and VADT.

Clinical Insights in Diabetes Newsletter December 2012

Top

Clinical Insights® in Diabetes newsletter December 2012 

Once-weekly exenatide vs once-daily liraglutide in DURATION-6, HDL-C and microvascular risk in ADVANCE, statins and valvular calcification in VADT, bariatric surgery and cardiovascular events in obesity and type 2 diabetes in SOS. 

Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT).

Top

Exclusive! Expert commentary webcast from Vivian Fonseca, MD, on this post-hoc analysis of VADT. Saremi A, Bahn G, Reaven PD; for the VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2012;35:2390-2392. Cross-sectional data from the Veterans Affairs Diabetes Trial (VADT) showed that participants with coronary artery or abdominal aortic calcification had an increased prevalence of cardiovascular disease, including peripheral artery disease and coronary artery disease.

NDEI.org Expert Commentary ACCORD BP Trial Henry Ginsberg

Top

Expert commentary from Henry Ginsberg, MD on post-hoc analysis of ACCORD BP trial examining the potential interaction between obesity and intensive blood pressure treatment on CVD outcomes.

1 2 3 Next 

Slide Library Results

Search Results for: ACCORD Slides Found: 38
ACCORD: Study Design
ACCORD: Results
ACCORD Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ACCORD Trial: CV Events With Intensive Blood Glucose Control
Type 2 Diabetes Therapy and Cardiovascular Events: Comparing VADT With Other Trials
ACCORD-MIND: Relationship Between Glycemia Status, Diabetes Duration, and Cognitive Test Scores
ACCORD-MIND: Relationship Between Glycemia Status, CVD, Stroke, Smoking Status, and Cognitive Test Scores
Meta-Analysis: Intensive vs Standard Glucose Treatment on A1C Concentration at Follow-Up
Meta-Analysis: Intensive vs Standard Glucose Treatment on Non-Fatal Myocardial Infarc
Meta-Analysis: Intensive vs Standard Glucose Treatment on CHD
Meta-Analysis: Conclusion
ACCORD: A1C and Mortality Risk
ACCORD: Annual Incidence of Hypoglycemia in the Intensive Versus Standard Treatment Groups
ACCORD: Hypoglycemia and Mortality
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
ACCORD Substudy: Impact of Frequent and Unrecognized Hypoglycemia on Mortality—Design
ACCORD Substudy: Impact of Frequent and Unrecognized Hypoglycemia on Mortality—Results
Diabetic Retinopathy and Incident CV Events in ACCORD
Diabetic Retinopathy and Incident CV Events in ACCORD: Results
ACCORD: Death from Any Cause
Weight Gain from Type 2 Diabetes Treatment in ACCORD
Weight Gain in ACCORD By Type 2 Diabetes Treatment Allocation
Relationship Between Change in Weight and Change in A1C in ACCORD
Medication Use and Weight Gain in ACCORD
ACCORD-MIND Hypoglycemia Brain Structure Type 2 Diabetes | NDEI
ACCORD-MIND Hypoglycemia Age, Intensive Therapy, Diabetes Duration | NDEI
ACCORD-MIND Hypoglycemia Doesn't Alter Brain Function Type 2 Diabetes | NDEI
ACCORD-MIND Summary Hypoglycemia Cognitive Function Type 2 Diabetes | NDEI
Individualized Diabetes Therapy for CVD Prevention in Type 2 Diabetes AHA ADA | NDEI
Hypoglycemia & CVD Risk Type 2 Diabetes AHA ACC Guidelines PPT | NDEI
ACCORD BP Post-hoc Analysis: Design
ACCORD BP Post-hoc Analysis: Secondary Outcomes by Waist/Height Quartiles
ACCORD BP Post-hoc Analysis:Outcomes by Treatment Group, Waist-to-Height Quartiles
ACCORD BP Post-hoc Analysis: Primary Outcome by Waist/Height Quartiles
ACCORD: Factors Associated with Increased Hypoglycemia Risk in Intensive and Standard Treatment Arms